https://hstalks.com/category/754/pharmaceutical-sciences/?biosci New and updated series & talks on Pharmaceutical Sciences from HSTalks' Biomedical & Life Sciences Collection. daily 1 2006-01-01T12:00+00:00 Henry Stewart Talks en © Copyright Henry Stewart Talks Ltd. The Biomedical & Life Sciences Collection © Copyright Henry Stewart Talks Ltd. https://hstalks.com/t/27019/clinical-trial-endpoints/?biosci Role of trial endpoints - Types of trial endpoints - Pre-specification of endpoints - Surrogate endpoints use and validation - Statistical vs clinical significance - Endpoint selection impact - Regulatory requirements for endpoints Clinical trial endpoints Role of trial endpoints, Types of trial endpoints, Pre-specification of endpoints, Surrogate endpoints use and validation, Statistical vs clinical significance, Endpoint selection impact, Regulatory requirements for endpoints 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27025/dose-response-relationships/?biosci Dose-response basics - Emax model applications - Potency vs efficacy - Therapeutic window & optimization - Patient variability in dosing - Dose-response in early trials - Drug monitoring & personalized dosing Dose-response relationships Dose-response basics, Emax model applications, Potency vs efficacy, Therapeutic window & optimization, Patient variability in dosing, Dose-response in early trials, Drug monitoring & personalized dosing 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci Ongoing clinical trials for bladder cancer - Enfortumab-vedotin & pembrolizumab as first-line therapy - Disitamab vedotin & toripalimab (PD1 inhibitor) for the treatment of metastatic UC - Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions - Remission with cisplatin-based NAC - mRNA-4157 (V940): customizable individualized mRNA immunotherapy - Adjuvant chemotherapy - Neoadjuvant Chemo-IO combination therapy Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials Prof. Guru P. Sonpavde Ongoing clinical trials for bladder cancer, Enfortumab-vedotin & pembrolizumab as first-line therapy, Disitamab vedotin & toripalimab (PD1 inhibitor) for the treatment of metastatic UC, Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions, Remission with cisplatin-based NAC, mRNA-4157 (V940): customizable individualized mRNA immunotherapy, Adjuvant chemotherapy, Neoadjuvant Chemo-IO combination therapy 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/22202/us-privacy-law-and-digital-therapeutics/?biosci Digital Therapeutics - Digital Health - Virtual Care - US FDA - HIPAA - Privacy - Security - US FTC U.S. privacy law and digital therapeutics Ms. Lucia C. Savage Digital Therapeutics, Digital Health, Virtual Care, US FDA, HIPAA, Privacy, Security, US FTC 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27030/safety-signal-detection/?biosci Safety signal detection - Preclinical safety assessment - Clinical safety monitoring - Post-marketing pharmacovigilance - Adverse reaction methodologies - Data quality challenges - Regulatory safety responses Safety signal detection Safety signal detection, Preclinical safety assessment, Clinical safety monitoring, Post-marketing pharmacovigilance, Adverse reaction methodologies, Data quality challenges, Regulatory safety responses 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27029/biomarker-development-and-application/?biosci Biomarker discovery with omics - Data integration with clinical info - Analytical and clinical validation - Types and roles of biomarkers - Biomarkers in precision medicine - Regulatory pathways for biomarkers - Cross-disciplinary collaboration in biomarker development Biomarker development and application Biomarker discovery with omics, Data integration with clinical info, Analytical and clinical validation, Types and roles of biomarkers, Biomarkers in precision medicine, Regulatory pathways for biomarkers, Cross-disciplinary collaboration in biomarker development 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27043/rt-pcr-vs-qpcr/?biosci RT-PCR vs qPCR principles - Nucleic acid amplification - CDNA synthesis in RT-PCR - Real-time quantification in qPCR - Endpoint vs real-time analysis - Medical diagnostics applications - Technical challenges and limitations RT-PCR vs qPCR RT-PCR vs qPCR principles, Nucleic acid amplification, CDNA synthesis in RT-PCR, Real-time quantification in qPCR, Endpoint vs real-time analysis, Medical diagnostics applications, Technical challenges and limitations 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27032/antibodies-vs-small-molecules/?biosci Antibody vs Small Molecule - Mechanisms & Pharmacokinetics - Drug Size Structure & Administration - Clinical Applications & Selection - Antibody vs Small Molecule Pros & Cons - Target Accessibility & Specificity - Innovations in Drug Development Antibodies vs small molecules Antibody vs Small Molecule, Mechanisms & Pharmacokinetics, Drug Size Structure & Administration, Clinical Applications & Selection, Antibody vs Small Molecule Pros & Cons, Target Accessibility & Specificity, Innovations in Drug Development 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27027/pharmacodynamics-vs-pharmacokinetics/?biosci Pharmacokinetics vs Pharmacodynamics - ADME processes - Drug interactions with targets - Dose-response relationships - Integration of PK/PD in therapy - PK/PD modeling - Individualized and evidence-based prescribing Pharmacodynamics vs pharmacokinetics Pharmacokinetics vs Pharmacodynamics, ADME processes, Drug interactions with targets, Dose-response relationships, Integration of PK/PD in therapy, PK/PD modeling, Individualized and evidence-based prescribing 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27035/drug-pricing-and-reimbursement/?biosci Drug pricing models (cost-plus, value-based, intl. ref.) - Health Technology Assessment (HTA) in reimbursement - Cost-effectiveness analysis with QALY - Global payer systems and reimbursement pathways - Drug pricing, access, affordability by country - Balancing innovation, sustainability, equitable access Drug pricing and reimbursement Drug pricing models (cost-plus, value-based, intl. ref.), Health Technology Assessment (HTA) in reimbursement, Cost-effectiveness analysis with QALY, Global payer systems and reimbursement pathways, Drug pricing, access, affordability by country, Balancing innovation, sustainability, equitable access 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27037/pharmaceutical-lifecycle/?biosci Pharmaceutical lifecycle stages - Drug discovery & preclinical development - Clinical trials & regulatory approval - Intellectual property & exclusivity management - Commercialization & market expansion strategies - Generic competition after patent expiration - Lifecycle management & sustained innovation Pharmaceutical lifecycle Pharmaceutical lifecycle stages, Drug discovery & preclinical development, Clinical trials & regulatory approval, Intellectual property & exclusivity management, Commercialization & market expansion strategies, Generic competition after patent expiration, Lifecycle management & sustained innovation 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27033/monotherapy-vs-combination-therapy/?biosci Monotherapy vs Combination Therapy definitions - Disease treatment applications - Benefits & limitations of therapies - Resistance, efficacy, toxicity, adherence - Clinical trial evidence in therapy choices - Individualized, evidence-based decisions Monotherapy vs combination therapy Monotherapy vs Combination Therapy definitions, Disease treatment applications, Benefits & limitations of therapies, Resistance, efficacy, toxicity, adherence, Clinical trial evidence in therapy choices, Individualized, evidence-based decisions 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27036/market-access-in-pharma/?biosci Key principles of pharma market access - Regulatory approval vs reimbursement - Reimbursement challenges in healthcare systems - Health economic evaluations (cost-effectiveness, budget impact) - Market access strategies (payer engagement, pricing, evidence) Market access in pharma Key principles of pharma market access, Regulatory approval vs reimbursement, Reimbursement challenges in healthcare systems, Health economic evaluations (cost-effectiveness, budget impact), Market access strategies (payer engagement, pricing, evidence) 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27024/hit-to-lead-process/?biosci Hit-to-Lead stages - Screening and hit ID - Hit triage and criteria - SAR studies - Early ADMET - Scientific disciplines and risk - Technologies in hit-to-lead Hit-to-lead process Hit-to-Lead stages, Screening and hit ID, Hit triage and criteria, SAR studies, Early ADMET, Scientific disciplines and risk, Technologies in hit-to-lead 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27021/patient-recruitment-and-retention/?biosci Patient recruitment and retention - Barriers to recruitment - Inclusion and exclusion criteria - Strategies for retention and engagement - Diversity and equity in research - Ethical considerations in recruitment - Decentralized and patient-centric trials Patient recruitment and retention Patient recruitment and retention, Barriers to recruitment, Inclusion and exclusion criteria, Strategies for retention and engagement, Diversity and equity in research, Ethical considerations in recruitment, Decentralized and patient-centric trials 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/22333/ich-s12-nonclinical-biodistribution-considerations/?biosci Chapters of ICHS12 - Introduction (Objective and scope) - Definition of non-clinical (NC) biodistribution (BD) studies - Timing of BD studies - Design of BD studies - ICHS12: Specific considerations - Applications of BD studies ICH S12: nonclinical biodistribution considerations for gene therapy products Dr. Tineke van den Hoorn Chapters of ICHS12, Introduction (Objective and scope), Definition of non-clinical (NC) biodistribution (BD) studies, Timing of BD studies, Design of BD studies, ICHS12: Specific considerations, Applications of BD studies 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27044/applications-of-cell-culture-in-drug-development/?biosci Cell culture fundamentals - Cell culture requirements - Cell line types in research - Cell culture in drug development - Drug screening using cell culture - Limitations of cell culture models Applications of cell culture in drug development Cell culture fundamentals, Cell culture requirements, Cell line types in research, Cell culture in drug development, Drug screening using cell culture, Limitations of cell culture models 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27028/therapeutic-window-and-safety-margins/?biosci Therapeutic window and index - Effective vs toxic dose - Patient factors in drug response - Dosing decisions and monitoring - Narrow therapeutic index drugs Therapeutic window and safety margins Therapeutic window and index, Effective vs toxic dose, Patient factors in drug response, Dosing decisions and monitoring, Narrow therapeutic index drugs 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/22696/digital-health-technologies-dhts-for-drug-developm/?biosci Digital health technologies - CNS - Parkinson’s disease - WATCH PD - Critical Path Institute - Rare neurodegenerative disease - Public private partnership model Digital health technologies (DHTs) for drug development in CNS diseases Dr. Diane T. Stephenson Digital health technologies, CNS, Parkinson’s disease, WATCH PD, Critical Path Institute, Rare neurodegenerative disease, Public private partnership model 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27020/adaptive-clinical-trial-designs/?biosci Adaptive Clinical Trials - Interim Analyses - Response-Adaptive Randomisation - Statistical Error Control - Regulatory Requirements - Advantages Over Fixed Designs - Operational Planning Adaptive clinical trial designs Adaptive Clinical Trials, Interim Analyses, Response-Adaptive Randomisation, Statistical Error Control, Regulatory Requirements, Advantages Over Fixed Designs, Operational Planning 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27026/receptor-theory-in-pharmacology/?biosci Receptor-ligand binding - Agonists vs antagonists - Allosteric modulation - Affinity and specificity - Receptor occupancy theory - Clinical drug examples - Receptor theory in drug development Receptor theory in pharmacology Receptor-ligand binding, Agonists vs antagonists, Allosteric modulation, Affinity and specificity, Receptor occupancy theory, Clinical drug examples, Receptor theory in drug development 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27031/drug-modality-selection/?biosci Drug modality selection - Types of drug modalities - Modality advantages and challenges - Delivery and stability - Matching modalities to disease - Practical considerations for modalities - Modality limitations and constraints Drug modality selection Drug modality selection, Types of drug modalities, Modality advantages and challenges, Delivery and stability, Matching modalities to disease, Practical considerations for modalities, Modality limitations and constraints 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27023/drug-target-landscape/?biosci Drug target classification - Drug-target interaction mechanisms - Druggability assessment - Drug-target engagement examples - Advances in drug target discovery Drug target landscape Drug target classification, Drug-target interaction mechanisms, Druggability assessment, Drug-target engagement examples, Advances in drug target discovery 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/27022/target-identification-in-practice/?biosci Target ID principles & importance - Omics & computational advances - Data-driven disease profiling - Functional validation: RNAi & CRISPR - Pathway & systems biology integration - Rigorous target validation strategies Target identification in practice Target ID principles & importance, Omics & computational advances, Data-driven disease profiling, Functional validation: RNAi & CRISPR, Pathway & systems biology integration, Rigorous target validation strategies 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/22729/biomedicines-extraordinary-opportunities-amidst-un/?biosci Evolution of the FDA - Eroom’s law - Blockbuster and me-too drugs - Eli Lilly as an innovator - Impact of mergers on biomedicine research - Industry consolidation and its impact - Impact of academia on biomedicines Biomedicines: extraordinary opportunities amidst uncertain times Prof. Michael Kinch Evolution of the FDA, Eroom’s law, Blockbuster and me-too drugs, Eli Lilly as an innovator, Impact of mergers on biomedicine research, Industry consolidation and its impact, Impact of academia on biomedicines 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/21706/driving-patient-centricity-in-pharmacovigilance-a-/?biosci Patient centricity - Pharmacovigilance - Patient engagement - Risk management - Patient safety - Industry best practices Driving patient centricity in pharmacovigilance: a global to local implementation framework Ms. Farai Moyo Patient centricity, Pharmacovigilance, Patient engagement, Risk management, Patient safety, Industry best practices 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/22663/drug-safety/?biosci Drug benefits and adverse effects - Mechanism of drug toxicity - Drug metabolism and toxicity - Individual human toxicity - Drug cytotoxicity and genotoxicity - Drug toxicity screening - Teratogenicity Drug safety Dr. Wayne Carter Drug benefits and adverse effects, Mechanism of drug toxicity, Drug metabolism and toxicity, Individual human toxicity, Drug cytotoxicity and genotoxicity, Drug toxicity screening, Teratogenicity 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/21475/psoriasis-diagnosis-overview/?biosci Clinical identification of psoriasis - Pathogenesis - Classification of psoriasis - Psoriatic arthritis - Enthesitis - Comorbidities in psoriatic disease - Malignancy and psoriasis - Quality of life in psoriasis Psoriasis: diagnosis & overview Dr. Tina Bhutani Clinical identification of psoriasis, Pathogenesis, Classification of psoriasis, Psoriatic arthritis, Enthesitis, Comorbidities in psoriatic disease, Malignancy and psoriasis, Quality of life in psoriasis 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/17812/drug-discovery-and-development/?biosci Drug design economics - Drug specificity and efficacy - Structure- activity relationships - Drug targets - Drug safety assessment Drug discovery and development Dr. Wayne Carter Drug design economics, Drug specificity and efficacy, Structure- activity relationships, Drug targets, Drug safety assessment 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/22201/ich-s5r3-detection-of-reproductive-and-development/?biosci Medicines and pregnancy - Developmental and reproductive toxicity (DART) - Fertility and Early Embryonic Development (FEED) - Embryo-Fetal Development (EFD) - Pre- and Postnatal Development (PPND) - Considerations in pharmaceuticals - Principles of integrated risk assessment ICH S5(R3): detection of reproductive and developmental toxicity for human pharmaceuticals Dr. Günter Waxenecker Medicines and pregnancy, Developmental and reproductive toxicity (DART), Fertility and Early Embryonic Development (FEED), Embryo-Fetal Development (EFD), Pre- and Postnatal Development (PPND), Considerations in pharmaceuticals, Principles of integrated risk assessment 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/21937/capillary-gel-electrophoresis-2/?biosci High-performance capillary gel electrophoresis (CGE) - Non-denaturing capillary polyacrylamide gel electrophoresis - Micropreparative capillary gel electrophoresis - SDS-PAGE vs. SDS-CGE - Transitionally cross-linked sieving matrices - Coaxial sheath flow reactor CGE-ESI-MS interface - Techniques used for solubilized and immobilized affinity ligands in CGE Capillary gel electrophoresis 2 Prof. Dr. András Guttman High-performance capillary gel electrophoresis (CGE), Non-denaturing capillary polyacrylamide gel electrophoresis, Micropreparative capillary gel electrophoresis, SDS-PAGE vs. SDS-CGE, Transitionally cross-linked sieving matrices, Coaxial sheath flow reactor CGE-ESI-MS interface, Techniques used for solubilized and immobilized affinity ligands in CGE 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/20023/in-silico-selection/?biosci Molecular modelling benefits - Molecular predictions - Docking studies - Binding affinities - In silico druglikeness prediction - Lipinski's rule of five In silico selection Dr. Wayne Carter Molecular modelling benefits, Molecular predictions, Docking studies, Binding affinities, In silico druglikeness prediction, Lipinski's rule of five 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection